Robust Clinical and Pre-Clinical Pipeline

KBP-5074:    Mineralocorticoid receptor antagonist for CV disease, including uncontrolled hypertension in advanced chronic kidney disease

  • Highly selective and potent non-steroidal MR-specific antagonist
  • Favorable long-term safety profile, potential for best in class safety and efficacy profile
  • Completed Phase 1 and Phase 2a trials, initiated global Phase 2b trial in Q1 2018
  • On-going collaboration with FDA to expedite development


KBP-7072:    3G aminomethylcycline for drug resistant infections across multiple indication

  • Next gen tetracycline effective against multiple drug-resistant Gram-positive strains, including MRSA, PRSP, VRE
  • Strong antibacterial activity against gram negative bacteria including Acinetobacter (WHO priority pathogens, Priority 1/Critical)
  • Completed Phase 1 trial and ready for global Phase 2
  • FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations awarded


KBP-7026:    Novel MOA (CRTH2  antagonist) targeting Asthma/COPD and other inflammatory diseases

  • Highly selective Chemoattractant Receptor‐Homologous Molecule expressed on Th2 lymphocytes (CRTH2) antagonist
  • Specific PK profile and wide safety window
  • IND approved by FDA and ready for Phase 1


KBP-7018:    Tri‐kinase inhibitor (blocks PDGFR, RET, and c‐KIT at nM concentrations) targeting fibrotic disease, especially idiopathic pulmonary fibrosis

  • Potentially best in class for all patients including severe IPF patients
  • Excellent selectivity and safety profile
  • Potent dose-dependent efficacy demonstrated in IPF model
  • PK profile suitable for once-daily dosing
  • Ready for IND-enabling studies


KBP-7536:    Dual BTK/JAK3 inhibitor for inflammatory and myeloproliferative diseases

  • Potent efficacy with good tolerability demonstrated in RA model
  • PK profile ideal for once-daily dosing
  • Ready for IND-enabling studies


Discovery Program:    LpxC inhibitor for Gram negative bacterial infections especially P. aeruginosa (WHO priority pathogens, Priority 1/Critical)

  • Lead optimization stage, Candidate Selection expected in 1H 2018
  • Excellent in vitro activity against Gram negative resistant bacteria including multi-drug resistant and pan-drug resistant Pseudomonas aeruginosa